Pharmaceutical R&D expenditure in Europe, USA and Japan

R&D process

R&D in Europe

Allocation of R&D investments

New chemical or biological entities

Estimated costs of bringing a new entity to market

Pharmaceutical R&D expenditure - Annual growth rate (%)

R&D intensity

Impact on the European economy

Geographical breakdown of sales of new medicines

R&D expenditure in Europe, USA and Japan

Parallel imports

Production

World pharmaceutical market

Market value

VAT rates

Generics

Imports and exports

Trade balance (by country)

Trade balance - high technology sectors

EU main pharmaceutical trading partners

Employment in the pharmaceutical industry (by country)

Employment in the pharmaceutical industry (by year)

Employment in pharmaceutical R&D

Total spending on healthcare

Payment for pharmaceuticals

Causes of death by major disease areas

Breakdown of health expenditure

New medicines

Cancer mortality

Cancer - life expectancy

Hep C - cure rates

Chronic diseases - impact

Vaccines - impact

HIV - death rates

Innovation

Personalised medicines - Leukemia survival

Personalised medicines - Lung cancer

Rare diseases

Medicines benefits

Health gains and savings

The added value of medicines

Shift towards cure and prevention

Medicines and total healthcare costs

Industry contribution to European economy

R&D spending by industry

R&D spending as a percentage of net sales

Value added per employee

Worldwide pharmaceutical R&D investment

UK pharmaceutical R&D investment

Innovative treatments – longevity and productivity of patients

Clinical Trials

Unmet medical needs

Cancer survivorship and employment

Healthcare systems – challenges

Ageing population

Chronic disease

Pharmaceutical expenditure

Pharmaceutical expenditure in Germany

Cancer-related healthcare costs

Cost-reduction of off-patent medicines

Generic medicines

Biosimilars

Health outcomes